$ATYRAug 7, 2026, 8:01 PMAI processed
aTyr cuts ~60% of staff to focus on efzofitimod in ILD; FDA feedback on Phase 3 protocol due end‐Aug
AI Summary
ATyr announced a corporate restructuring that will reduce headcount by approximately 60% to prioritize efzofitimod for interstitial lung disease and conserve cash while awaiting FDA feedback on a Phase 3 protocol submitted in June (response expected by the end of August 2026). The company has completed enrollment in the Phase 2 EFZO‐CONNECT SSc‐ILD study (23 patients) with topline results expected in Q1 2027, ended Q2 with $58.9M in cash and says the runway extends into late 2028 but will require additional capital to fund a global Phase 3.
Positives
- Submitted Phase 3 protocol for efzofitimod in pulmonary sarcoidosis; FDA feedback expected by end of August 2026
- Completed enrollment in Phase 2 EFZO‑CONNECT (SSc‑ILD); topline results expected in Q1 2027
- Restructuring and cost measures expected to reduce annualized operating expenses by ~$13M and extend runway into late 2028
Negatives
- Workforce reduction of ~60% could impair operational capacity and trial execution
- Only $58.9M in cash on June 30, 2026; company says additional capital will be required to run a global Phase 3
- CFO and General Counsel stepping down (transitioning to consultant roles), indicating leadership turnover during pivot